Bacterial delivery vehicle, process of production and uses thereof
US-2019390175-A1 · Dec 26, 2019 · US
Antibiotic-free plasmids
US9217153B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9217153-B2 |
| Application number | US-78618610-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 24, 2010 |
| Priority date | May 22, 2009 |
| Publication date | Dec 22, 2015 |
| Grant date | Dec 22, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides a method of maintaining a gram negative bacterium plasmid without the use of antibiotic selection pressure. Further, the invention relates to the drugless plasmids produced including drugless plasmids containing a heterologous gene. The invention also provides formulations and/or compositions comprising the drugless plasmids comprising a heterologous gene, formulations and/or compositions comprising a protein or an immunogen expressed using the drugless plasmids, and methods of administering such formulations and/or compositions to a host. The invention relates to gram negative bacteria containing the drugless plasmids.
First claim
Opening claim text (preview).
What is claimed is: 1. A drugless plasmid comprising a polynucleotide encoding a cI repressor protein comprising the sequence of SEQ ID NO:2, wherein the expression of the cI repressor protein regulates the expression of a heterologous toxic gene product in a bacterial host. 2. The drugless plasmid of claim 1 , wherein the polynucleotide is operably linked to a promoter. 3. The drugless plasmid of claim 2 , wherein the promoter is a P1 pro…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
- C12N15/73Primary
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9217153B2 cover?
- The present invention provides a method of maintaining a gram negative bacterium plasmid without the use of antibiotic selection pressure. Further, the invention relates to the drugless plasmids produced including drugless plasmids containing a heterologous gene. The invention also provides formulations and/or compositions comprising the drugless plasmids comprising a heterologous gene, formula…
- Who is the assignee on this patent?
- Audonnet Jean Christophe Francis, Jolivet Edmond, Merial Inc
- What technology area does this patent fall under?
- Primary CPC classification C12N15/73. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 22 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).